(XPEV) Xpeng - Ratings and Ratios
Electric Sedan, Electric SUV, Electric MPV, Electric Coupe, Smart Platform
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 73.0% |
| Value at Risk 5%th | 113% |
| Relative Tail Risk | -5.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.97 |
| Alpha | 46.82 |
| CAGR/Max DD | 0.39 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.285 |
| Beta | 0.845 |
| Beta Downside | 0.620 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.65% |
| Mean DD | 34.91% |
| Median DD | 30.05% |
Description: XPEV Xpeng December 19, 2025
XPeng Inc. (NYSE:XPEV) is a Chinese EV manufacturer that designs, builds, and sells a range of smart electric vehicles, including the P7/P7i sports sedan, G9 and G6 SUVs, the X9 seven-seat MPV, the MONA M03 hatchback coupe, and the performance-oriented P7+. The firm also develops the XOS Tianji in-car operating system, its proprietary SEPA 2.0 vehicle platform, and offers a suite of services such as supercharging, maintenance, financing, and insurance technology support. Founded in 2015 and headquartered in Guangzhou, XPeng operates primarily in the People’s Republic of China.
Recent data shows XPeng delivered roughly 30,000 vehicles in Q3 2024, a 45% year-over-year increase driven by strong demand for its G9 SUV and the newly launched MONA M03. The company’s cash balance stood at about $5.3 billion at the end of the quarter, providing runway for continued R&D, which now consumes roughly 12% of revenue. A key macro driver is China’s ongoing NEV subsidy program and tightening emission standards, which are expanding the addressable market for premium electric sedans and SUVs.
For deeper metrics and valuation insights, you might explore ValueRay’s XPEV dashboard.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-2.85b TTM) > 0 and > 6% of Revenue (6% = 4.23b TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -2.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.05% (prev 31.59%; Δ -22.54pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -2.01b > Net Income -2.85b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (952.7m) change vs 12m ago -49.54% (target <= -2.0% for YES) |
| Gross Margin 17.08% (prev 11.45%; Δ 5.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 80.77% (prev 49.47%; Δ 31.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.53 (EBITDA TTM -2.01b / Interest Expense TTM 553.2m) >= 6 (WARN >= 3) |
Altman Z'' -1.87
| (A) 0.06 = (Total Current Assets 59.95b - Total Current Liabilities 53.57b) / Total Assets 98.31b |
| (B) -0.44 = Retained Earnings (Balance) -43.13b / Total Assets 98.31b |
| (C) -0.04 = EBIT TTM -3.06b / Avg Total Assets 87.37b |
| (D) -0.60 = Book Value of Equity -41.08b / Total Liabilities 68.32b |
| Total Rating: -1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.62
| 1. Piotroski 3.50pt |
| 2. FCF Yield -3.39% |
| 3. FCF Margin -6.29% |
| 4. Debt/Equity 1.16 |
| 5. Debt/Ebitda -8.56 |
| 6. ROIC - WACC (= -13.23)% |
| 7. RoE -9.33% |
| 8. Rev. Trend 71.46% |
| 9. EPS Trend 70.06% |
What is the price of XPEV shares?
Over the past week, the price has changed by +3.80%, over one month by -4.81%, over three months by -10.39% and over the past year by +75.06%.
Is XPEV a buy, sell or hold?
- Strong Buy: 14
- Buy: 7
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the XPEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.5 | 37.2% |
| Analysts Target Price | 28.5 | 37.2% |
| ValueRay Target Price | 20 | -3.8% |
XPEV Fundamental Data Overview December 26, 2025
P/E Forward = 43.29
P/S = 0.2645
P/B = 4.3758
Beta = 1.051
Revenue TTM = 70.57b CNY
EBIT TTM = -3.06b CNY
EBITDA TTM = -2.01b CNY
Long Term Debt = 6.42b CNY (from longTermDebt, last quarter)
Short Term Debt = 23.23b CNY (from shortTermDebt, last quarter)
Debt = 34.70b CNY (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.17b CNY (from netDebt column, last quarter)
Enterprise Value = 130.81b CNY (130.81b + Debt 34.70b - CCE 34.70b)
Interest Coverage Ratio = -5.53 (Ebit TTM -3.06b / Interest Expense TTM 553.2m)
FCF Yield = -3.39% (FCF TTM -4.44b / Enterprise Value 130.81b)
FCF Margin = -6.29% (FCF TTM -4.44b / Revenue TTM 70.57b)
Net Margin = -4.04% (Net Income TTM -2.85b / Revenue TTM 70.57b)
Gross Margin = 17.08% ((Revenue TTM 70.57b - Cost of Revenue TTM 58.52b) / Revenue TTM)
Gross Margin QoQ = 20.14% (prev 17.33%)
Tobins Q-Ratio = 1.33 (Enterprise Value 130.81b / Total Assets 98.31b)
Interest Expense / Debt = 0.29% (Interest Expense 99.3m / Debt 34.70b)
Taxrate = 1.83% (-7.11m / -388.0m)
NOPAT = -3.00b (EBIT -3.06b * (1 - 1.83%)) [loss with tax shield]
Current Ratio = 1.12 (Total Current Assets 59.95b / Total Current Liabilities 53.57b)
Debt / Equity = 1.16 (Debt 34.70b / totalStockholderEquity, last quarter 29.99b)
Debt / EBITDA = -8.56 (negative EBITDA) (Net Debt 17.17b / EBITDA -2.01b)
Debt / FCF = -3.87 (negative FCF - burning cash) (Net Debt 17.17b / FCF TTM -4.44b)
Total Stockholder Equity = 30.58b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.90% (Net Income -2.85b / Total Assets 98.31b)
RoE = -9.33% (Net Income TTM -2.85b / Total Stockholder Equity 30.58b)
RoCE = -8.27% (EBIT -3.06b / Capital Employed (Equity 30.58b + L.T.Debt 6.42b))
RoIC = -5.95% (negative operating profit) (NOPAT -3.00b / Invested Capital 50.47b)
WACC = 7.27% (E(130.81b)/V(165.51b) * Re(9.13%) + D(34.70b)/V(165.51b) * Rd(0.29%) * (1-Tc(0.02)))
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -28.59%
Fair Price DCF = unknown (Cash Flow -4.44b)
EPS Correlation: 70.06 | EPS CAGR: 9.10% | SUE: 0.44 | # QB: 0
Revenue Correlation: 71.46 | Revenue CAGR: 26.04% | SUE: -0.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.30 | Chg30d=+0.533 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=2.61 | Chg30d=+0.260 | Revisions Net=+1 | Growth EPS=+357.7% | Growth Revenue=+42.5%
Additional Sources for XPEV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle